# Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

> **NCT03448718** · PHASE2 · COMPLETED · sponsor: **Matthew Galsky** · enrollment: 19 (actual)

## Conditions studied

- Metastatic Urothelial Cancer

## Interventions

- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT03448718
- **Lead sponsor:** Matthew Galsky
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-17
- **Primary completion:** 2021-07-14
- **Final completion:** 2021-10-15
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2023-11-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03448718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03448718, "Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03448718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*